Title: Study of the Proportion of Microalbuminuria in Non-Diabetic Patients

Authors: Dr Sarath Kumar S, Dr Radha T.R.

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i11.53

Abstract

Introduction

Ischemic heart disease is one of the known global killers and in India the estimated prevalence is approximately 6-9%. As of now it is a leading cause of mortality and morbidity in India.

Since the pioneering work of the Framingham study, many prospective and clinical studies have identified a series of independent risk factors for ischemic heart disease among which age, male gender, a positive family history of premature atherosclerotic disease, smoking, diabetes mellitus, hypertension, hypercholesterolemia, hypertriglyceridemia and low HDL cholesterol are considered as classical risk factors. The interest in improving cardiovascular risk assessment, resulting from a better understanding of the pathogenesis of atherosclerosis and identification of new targets for anti-atherosclerotic drug therapy has stimulated the search for novel risk factors.

References

  1. Suthar N, Khambholja J, Suthar A, Patel K, Parikh A. Relationship of Microalbuminuria with Ischemic Heart Disease in Non-Diabetic Subjects. NJIRM. (2014); 5(3): 51-56
  2. Khot UN, Khot MB, Bajzer CT, et al. PRevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003 Aug 20;290(7):898–904.
  3. Gupta RK, Gupta R, Maheshwari VD, Mawliya M. Impact of smoking on microalbuminuria and urinary albumin creatinine ratio in non-diabetic normotensive smokers. Indian J Nephrol. 2014;24(2):92–6.
  4. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000 Apr;23 Suppl 2:B35–9.
  5. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med. 2001 Jun;249(6):519–26.
  6. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med. 2000 Oct 17;133(8):585–91.
  7. Collins VR, Dowse GK, Finch CF, Zimmet PZ, Linnane AW. Prevalence and risk factors for micro- and macroalbuminuria in diabetic subjects and entire population of Nauru. Diabetes. 1989 Dec;38(12):1602–10.
  8. Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990 Feb 3;300(6720):297–300.
  9. Singh RB, Sharma JP, Rastogi V, Raghuvanshi RS, Moshiri M, Verma SP, et al. Prevalence of coronary artery disease and coronary risk factors in rural and urban populations of north India. Eur Heart J. 1997 Nov;18(11):1728–35.
  10. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia. 2008 Aug;51(8):1347–55.
  11. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet Lond Engl. 1988 Sep 3;2(8610):530–3.
  12. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984 Feb 9;310(6):356–60.
  13. Nelson RG, Kunzelman CL, Pettitt DJ, Saad MF, Bennett PH, Knowler WC. Albuminuria in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance in Pima Indians. Diabetologia. 1989 Dec;32(12):870–6.
  14. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1996 Oct;45(10):1289–98.
  15. Franciosi M, Pellegrini F, Sacco M, De Berardis G, Rossi MCE, Strippoli GFM, et al. Identifying patients at risk for microalbuminuria via interaction of the components of the metabolic syndrome: a cross-sectional analytic study. Clin J Am Soc Nephrol CJASN. 2007 Sep;2(5):984–91.
  16. Tapp RJ, Shaw JE, Zimmet PZ, Balkau B, Chadban SJ, Tonkin AM, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis Off J Natl Kidney Found. 2004 Nov;44(5):792–8.
  17. Diercks GF, van Boven AJ, Hillege HL, Janssen WM, Kors JA, de Jong PE, et al. Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J. 2000 Dec;21(23):1922–7.
  18. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–53.
  19. Al-Saffar HB, Nassir H, Mitchell A, Philipp S. Microalbuminuria in non-diabetic patients with unstable angina/non ST-segment elevation myocardial infarction. BMC Res Notes. 2015;8:371.

Corresponding Author

Dr Sarath Kumar S

Kottayam Medical College